[Federal Register: February 10, 2003 (Volume 68, Number 27)]
[Rules and Regulations]
[Page 6636-6644]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr10fe03-20]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Medicare & Medicaid Services
42 CFR Parts 405 and 419
[CMS-1206-CN2]
RIN 0938-AL19
Medicare Program; Changes to the Hospital Outpatient Prospective
Payment System and Calendar Year 2003 Payment Rates; and Changes to
Payment Suspension for Unfiled Cost Reports; Correction
AGENCY: Centers for Medicare & Medicaid Services (CMS), HHS.
ACTION: Correction of final rule with comment period.
-----------------------------------------------------------------------
SUMMARY: This document corrects errors that appeared in the final rule
with comment period published in the Federal Register on November 1,
2002, entitled ``Changes to the Hospital Outpatient Prospective Payment
System and Calendar Year 2003 Payment Rates; and Changes to Payment
Suspension for Unfiled Cost Reports.'' This notice is a supplement to
the November 1, 2002, final rule with comment period and to the
November 15, 2002, correction notice, which added section ``XVI. Waiver
of Proposed Rulemaking.''
EFFECTIVE DATE: January 1, 2003.
FOR FURTHER INFORMATION CONTACT: Anita Heygster, (410) 786-0378.
SUPPLEMENTARY INFORMATION:
I. Background
In FR Doc. 02-27548 of November 1, 2002 (67 FR 66719), there were
several technical errors. The errors include incorrect or potentially
misleading responses, incorrect description of comments, and revisions
to information contained in Addenda A and B. In some cases, the errors
were omissions, typographical errors, mathematical miscalculations or
were caused by inadvertent failure to perform calculations or perform
other functions as described in the final rule. We would ordinarily
publish a notice of proposed rulemaking in the Federal Register and
invite public comment on the proposed rule. This procedure can be
waived, however, if an agency finds good cause that a notice-and-
comment procedure is impracticable, unnecessary, or contrary to the
public interest and incorporates a statement of the finding and its
reasons in the rule issued. We find good cause to waive notice and
comment procedures for this correction notice as set forth in section
III, ``Waiver of Proposed Rulemaking and Waiver of 30-Day Delay in
Effective Date,'' below.
II. Correction of Errors
On page 66719, in column 2, in the definition of CPT, we cited the
2002 Current Procedural Terminology (CPT), although the CPT codes used
for the 2003 Hospital Outpatient Prospective Payment System (OPPS) are
those found in the American Medical Association's 2003 Current
Procedural Terminology. Remove 2002 and insert 2003.
On page 66724, in column 3, under the second line following
``Option 2:'', we incorrectly cited as a Healthcare Common Procedure
Coding System (HCPCS) code 703690. This is not a HCPCS code. Remove
703690 and insert 70390.
On page 66724, in column 3, under the forth line following ``Option
3:'', we incorrectly cited as a HCPCS code 7036736 and we omitted one
HCPCS code that was presented to the APC Panel as discussed in the
preamble. Remove 7036736 and insert 70373, 70120.
On page 66729, we inadvertently included two duplicate comments and
responses on the issue of whether to move endometrial ablation out of a
new technology Ambulatory Payment Classification (APC) for 2003. Remove
the first comment and response under the heading ``New Technology APC
Issues'' in column 2 and the second duplicative comment and response in
column 3. The comment and response on this issue appear correctly on
page 66737 (column 3, 4th comment and response). The comment and
response on page 66737 are the correct comment and response on this
issue; those being removed were mistakenly published.
On pages 66730, 66818, and 66914, we inadvertently included
incorrect information that we intended to replace with correct
information before publication of the final rule. Specifically, on page
66730, we inadvertently included an incorrect APC assignment for HCPCS
codes 77523 and 77525. Remove Table 3 entries for HCPCS codes 77523,
Proton Beam therapy intermediate, and 77525, Proton beam therapy
complex. On page 66818, remove Addendum A entry for APC 650, Proton
Beam Therapy. On page 66914, change the APC for HCPCS codes 77523 and
77525 from APC 650 to APC 712, and change payment and copayment amounts
as described in corrections to Addendum B. Remove the first full
response on page 66728, in column 3, and replace it with the following:
``Response: We agree that codes for simple proton beam radiation
therapy (CPT code 77522 and CPT code 77520) should be placed in a
different APC than codes for intermediary (CPT code 77523) and complex
(CPT code 77525) radiation therapy. However, it would be inappropriate
to return codes for simple proton beam therapy to APCs for new
technology services because we believe we have sufficient claims data
to integrate them into the OPPS. Therefore, we have placed them in APC
664.
However, we agree that claims data are not sufficiently robust for
us to move intermediate and complex proton beam therapy (CPT codes
77523 and 77525) out of APC 712. Therefore, we will retain these codes
in APC 712 for the 2003 OPPS.''
On page 66732, in column 1, in the first line carried over from the
preceding page, we incorrectly stated that HCPCS code G0258 was
effective on October 1, 2002, when it was effective April 1, 2002.
Remove ``October 1, 2002'', and insert ``April 1, 2002''. HCPCS code
G0258 was made effective April 1, 2002, and was removed effective
January 1, 2003. The effective date of January 1, 2003, which is shown
in Table 4--New G Codes for 2002 and 2003 for Which There are Final APC
Assignments, is correct because January 1, 2003, is the effective date
of the deletion of the code and the change of the status indicator to
X. The entry in Addendum B on page 66979 correctly shows the payment
amount and the minimum unadjusted copayment that will apply during the
removed code's grace period.
On page 66735, in column 2, the first response under item
4, we mistakenly said that the APC payment includes both the
cost of the procedure and the cost for the left ventricular lead.
Remove the sentence that says: ``We believe the APC placement accounts
for the cost of
[[Page 6637]]
the procedure and for the lead.'' Insert the following sentence in its
place: ``The APC payment accounts for the cost of the procedure and
cost of the left ventricular lead is billed under the appropriate
device category ``C'' code.''
On page 66741, in column 1, we failed to acknowledge and address a
comment that objected to removing CPT code 92986 from the inpatient
only list. Remove the response in this column and replace it with the
following: ``Response: We agree with the commenters and with the APC
Panel's recommendations that CPT code 47001 be payable under the OPPS
beginning in 2003. Because this is an add-on code, payment will be
packaged with the payment for the surgical procedure with which it is
billed. We are making final our proposal to remove this code from the
inpatient list but we will consider presenting this concern to the APC
panel.
``The comment that urged that CPT code 92986, Percutaneous balloon
valvuloplasty; aortic value, not be assigned to APC 0083 did not
contain an explanation for the allegation that it cannot be performed
safely in an outpatient setting. In the absence of such justification
and in the absence of other comments disagreeing with our proposal to
pay under the OPPS for the 41 CPT codes listed in Table 6 of the August
2002 proposed rule (67 FR 52115), we are making these proposed changes
final.''
On page 66745, in Table 6, we included an incorrect APC assignment
for an APC. Remove 693A and insert 648. APC 693 was split into two APCs
to enable us to establish a weight for the services that require
devices based on the claims on which the devices were billed. The APC
with devices is APC 648, Breast Reconstruction with Prosthesis. It was
properly shown in Addendum A of the November 1, 2002, final rule.
On page 66756, in column 2, at the end of the first complete
paragraph, replace the comma after ``misuse'' with a period, and remove
the following words ``or received marketing approval based on the use
of surrogate outcomes.'' We never intended to perform reasonable and
necessary determinations on new technology solely because FDA marketing
approval was based on surrogate outcomes.
On page 66760, in Table 9, in the section titled ``Pass-through
Devices Effective January 2003,'' we reversed the HCPCS codes for two
items in the table (HCPCS codes C2614 and C2632). Remove HCPCS code
C2614 and APC 2614 and replace them with HCPCS code C2632 and APC 2632.
In the same location, remove HCPCS code C2632 and APC 2632 and replace
them with HCPCS code C2614 and APC 2614.
On page 66768, in column 1, first comment at the top of the column,
we incorrectly printed an exact replica of the immediately preceding
comment. Remove the duplicate comment.
On page 66772, we failed to include a drug that meets our criteria
as an orphan drug. HCPCS code J1785, Injection imiglucerase/unit meets
the criteria for an orphan drug as specified in the November 1, 2001,
final rule on page 66772. Remove the first full response in column 3
and replace it with the following: ``Response: After reviewing the
comments and reexamining whether there were other orphan drugs than the
three we proposed to pay separately, we have decided to remove four
orphan drugs that do not have any other non-orphan indications from the
OPPS system and will pay them on a reasonable cost basis. In addition
to the three drugs we proposed to treat as orphan drugs in the August
9, 2002, proposed rule, we have determined that J1785, Injection
imiglucerase/unit, meets the criteria of having no indication other
than an orphan indication and therefore meets our definition of an
orphan drug and will be paid on a reasonable cost basis. Other drugs
that have orphan status according to the FDA will be partly protected
by the dampening options described in section III.B. of this final
rule.'' On page 66820, remove all Addendum A entries for APC 0916. On
page 66983, under CPT/HCPCS code J1785, remove status indicator K and
insert status indicator F. Remove the APC number, relative weight,
payment amount, and minimum unadjusted copayment. See these changes in
Tables 1 and 2.
On page 66778, in the first response in column 1, we erroneously
said that APC 312 is the lowest paying brachytherapy APC. Remove the
response to the first comment under ``Brachytherapy'' and replace it
with the following: ``Response: The time frame of the claims used to
set payment rates in the final rule differed from the time frame used
in the proposed rule. According to the claims data used for the
proposed rule, APC 312 was the lowest paying brachytherapy APC.
However, according to the claims data used for the final rule, APC 0313
is the lowest paying brachytherapy APC. Therefore, CPT 77799 will
remain in APC 313. This is consistent with our policy of assigning
unspecified codes to the lowest paying similar APC because we do not
know what procedures are being performed. Moreover, we do not apply the
two times rule to unspecified codes like 77799 for the same reason. In
2003, CPT code 77799 is assigned to APC 0313.''
On pages 66779, 66780, and 66781, our discussions of the use of the
Red Book in the setting of payment rates for pass-through drugs may
have been misleading because we had misunderstandings regarding Red
Book publications. The Red Book issues one comprehensive annual printed
version, and it was our intent to convey that we relied on the most
recent comprehensive annual printed version of the Red Book to set the
pass-through payments for drugs for the 2003 OPPS. Our discussions of
the Red Book in the November 1, 2002, Federal Register erroneously
suggested that we rely on updates other than the comprehensive annual
printed version. The corrections below clarify that we rely on the
comprehensive annual printed version of the Redbook (which is printed
once a year) to set the payment rates for pass-through drugs and that
we intend to continue to do so in the future.
On page 66779, in column 3, in the last paragraph, delete the
second sentence and insert the following: ``We update the APC rates for
drugs that are eligible for pass through payments in 2003 using the
comprehensive annual printed version of the Red Book.''
On page 66780, remove the following beginning on the first line of
column 1 of page 66780: ``,* * * when we would again * * * update the
AWPs for any pass-through drugs based on the latest quarterly version
of the Red Book.'' Insert a period.
On page 66781, remove the first paragraph of the response beginning
at the bottom of column 1 of page 66781 and insert: ``Response: Upon
considering the commenters suggestions that we use the October 2002 Red
Book to set the pass-through rates for drugs and biologicals, we
decided to continue using the comprehensive annual printed version of
the Red Book since it is most consistent with our publication schedule.
In the future, for all of our final rules that must be published by
November, we intend to use the comprehensive annual printed version of
the Red Book.''
On page 66781, column 2, last response, remove the response and
insert: ``Response: As stated elsewhere in this final rule, we update
the payment rates for pass-through drugs and biologicals only on an
annual basis using the information published in the annual
comprehensive printed version of the Red Book. We rely upon the Red
Book to accurately reflect information supplied by manufacturers.''
[[Page 6638]]
On page 66795, in column 3, in the first comment, we mistakenly
said that everyone agreed with our proposal, although we received one
comment that opposed the proposed policy, not for reasons related to
payment under the OPPS. On page 66795, remove ``Everyone'' and replace
it with ``Many commenters.''
On page 66796, in column 2, in the fifth full paragraph, in the
last sentence, we mistakenly included the word ``final'' in describing
the diagnosis information needed to justify separate payment for
observation services. Our systems review all diagnoses reported on the
claim to make this decision. Remove the word ``final''.
On page 66815, for APC 0162, we incorrectly stated the relative
weight, payment rate, and minimum unadjusted copayment. The values in
the November 1, 2002, final rule for this APC were incorrect because we
failed to recalculate the values after moving CPT/HCPCS codes into and
out of this APC as we discussed in the November 1, 2002, final rule (67
FR 66736, 66746-66749).
Remove the relative weight, payment rate, and minimum unadjusted
copayment and replace them with a relative weight of 20.7844, payment
rate of $1,083.93, and minimum unadjusted copayment of $216.79. See
Table 2--Corrections to Addendum B of the November 1, 2002, Final Rule
for corrections to Addendum B for the codes assigned to APC 162.
On page 66815, for APC 0163, we incorrectly stated the relative
weight, payment rate, and minimum unadjusted copayment. The values in
the November 1, 2002, final rule for this APC were incorrect because we
failed to recalculate the values after moving CPT/HCPCS codes into and
out of this APC 163 as we discussed in the November 1, 2002, final rule
(67 FR 66736, 66746-66749). Remove relative weight, payment rate, and
minimum unadjusted copayment and insert a relative weight of 32.2861,
payment rate of $1,683.75, and minimum unadjusted copayment of $336.75.
See Table 2--Corrections to Addendum B of the November 1, 2002, Final
Rule for corrections to Addendum B for the codes assigned to APC.
On page 66816, for APC 0235, we incorrectly stated the relative
weight, payment rate, and minimum unadjusted copayment. The values in
the November 1, 2002, final rule for this APC were incorrect because we
failed to recalculate the values after moving CPT/HCPCS codes into and
out of this APC as we discussed in the November 1, 2002, final rule (67
FR 66725, 66746-66749). Remove the relative weight, payment rate, and
minimum unadjusted copayment and replace them with a relative weight of
4.9902, payment rate of $260.24, and minimum unadjusted copayment of
$72.04. See Table 2--Corrections to Addendum B of the November 1, 2002,
Final Rule for corrections to Addendum B for the codes assigned to APC
0235.
On page 66820, under APC 0905, we misstated the correct description
of the APC group title. Remove from the group title ``Immune globulin
500 mg'' and replace it with ``Immune globulin, 1 g''. On page 66983,
under CPT/HCPCS J1561, we assigned J1561 to an incorrect status
indicator. Remove status indicator K and replace it with status
indicator E. Remove the APC number, relative weight, payment rate, and
minimum unadjusted copayment. Also on page 66983, under HCPCS/CPT
J1563, we misstated the correct description of J1563 and did not
include the correct payment information. Remove description ``IV immune
globulin'' and status indicator E and replace them with ``Immune
globulin, 1 g'' and status indicator K. Insert APC 0905, relative
weight of 0.8333, payment rate of $43.46, and minimum unadjusted
copayment of $8.69. The corrections are also shown on Tables 1 and 2 of
this correction notice.
On page 66821, for APC 1045, group title Iobenguane sulfate 1-31
per 0.5 mCi, and on page 66958 for CPT/HCPCS code A9508, we stated
incorrect values because the limitations on the reduction in median
costs were inadvertently omitted. On page 66821, for APC 1045, remove
the relative weight, payment rate, and minimum unadjusted copayment and
insert a relative weight of 3.8662, payment rate of $201.63, and
minimum unadjusted copayment of $40.33. Also, on page 66821, we
misstated the correct description of the APC group title. Remove from
the group title ``I-31per'' and replace it with ``I-131 per''. On page
66958, for CPT/HCPCS code A9508, remove the relative weight, payment
rate, and minimum unadjusted copayment and insert a relative weight of
3.8662, payment rate of $201.63, and minimum unadjusted copayment of
$40.33.
As a result of a technical recalculation to Eptifibatide Injection,
CPT/HCPCS code J1327, the median cost for this drug exceeds the
threshold used for determining whether a drug qualifies for a separate
APC. To reflect this change, on page 66821, insert APC 1607, group
title of Eptifibatide Injection, 5 mg, status indictor of K, relative
weight of 0.1453, payment rate of $7.58, minimum unadjusted copayment
of $1.52.
On page 66821, under APC 2616, Brachytx seed, Yttrium-90, and on
page 66961, under HCPCS code C2616, we inserted incorrect values. We
made an error in calculation of the relative weight, payment rate, and
copayment. On page 66821, remove the relative weight, payment amount,
and minimum unadjusted copayment and insert a relative weight of
124.3576, payment amount of $6,485.37, and minimum unadjusted copayment
amount of $1,297.07. On page 66961, under CPT/HCPCS code C2616,
description Brachytx seed, Yttrium-90, remove the relative weight,
payment amount, and minimum unadjusted copayment and insert a relative
weight of 124.3576, payment amount of $6,485.37, and minimum unadjusted
copayment amount of $1,297.07.
On page 66822, for APC 9015, Mycophenolate mofetil oral 250 mg, and
on page 66986, under HCPCS code J7517, we failed to include the correct
status indicator, relative weight, payment rate, and copayment. Remove
the status indicator, relative weight, payment rate, and minimum
unadjusted copayment for APC 9015 on page 66822 and insert a status
indicator of G, payment rate of $2.53, and minimum unadjusted copayment
of $0.38. On page 66986, under CPT/HCPCS code J7517, description
Mycophenolate mofetil oral 250 mg, remove the status indicator,
relative weight, payment rate, and minimum unadjusted copayment and
insert a status indicator of G, payment rate of $2.53, and minimum
unadjusted copayment of $0.38. These corrections are also shown in
Tables 1 and 2 of this correction notice.
On page 66822, under APC 9112, group title Perflutren lipid micro,
per 2 ml, and on page 66961, under HCPCS code C9112, we failed to
include the correct payment and copayment rates. On page 66822, remove
the payment rate and minimum unadjusted copayment and insert a payment
rate of $148.20 and minimum unadjusted copayment of $22.15. On page
66961, under CPT/HCPCS code C9112, description Perflutren lipid micro,
per 2 ml, remove the payment rate and minimum unadjusted copayment and
insert a payment rate of $148.20 and minimum unadjusted copayment of
$22.15. These corrections are also shown in Tables 1 and 2 of this
correction notice.
On page 66822 for APC 9114 we incorrectly stated the description of
the APC, and we stated incorrect payment and copayment information. On
page 66822, remove the description of the APC and the payment and
copayment information and insert the following:
[[Page 6639]]
APC description of Nesiritide, per 0.5 mg vial, payment amount of
$144.40, and unadjusted national copayment amount of $21.58. On page
66984 for HCPCS code J2324, we incorrectly stated the description of
the HCPCS code, and we stated incorrect payment and copayment
information. On page 66984, remove the description of HCPCS code J2324
and the payment and copayment information and insert the following:
Description of Nesiritide, per 0.5 mg vial, payment amount of $144.40,
and unadjusted national copayment amount of $21.58.
On page 66822 for APC 9115, we incorrectly stated the description
of the APC, and we stated incorrect payment and copayment information.
On page 66822, remove the description of the APC and the payment and
copayment information and insert the following: APC description of Inj,
zoledronic acid, per 1 mg, payment amount of $203.39, and unadjusted
national copayment amount of $30.40. On page 66985 for HCPCS code
J3487, we incorrectly stated the description of the HCPCS code, and we
stated incorrect payment and copayment information. Remove the
description of HCPCS code J3487 and the payment and copayment
information and insert the following: Description of Inj, zoledronic
acid, per 1 mg, payment amount of $203.39, and unadjusted national
copayment amount of $30.40.
On page 66822, under APC 9120, group title Inj. Fulvestrant, per 50
mg, and on page 66962, under CPT/HCPCS code C9120, we failed to include
the correct payment and copayment. Remove the payment rate and minimum
unadjusted copayment and insert a payment rate of $175.16 and minimum
unadjusted copayment of $26.18. On page 66962, under CPT/HCPCS code
C9120, remove the payment rate and minimum unadjusted copayment and
insert a payment rate of $175.16 and minimum unadjusted copayment of
$26.18. These corrections are also shown in Tables 1 and 2.
On page 66847, we incorrectly assigned status code N to CPT/HCPCS
code 27096, inject sacroiliac joint. Two new codes, G0259, inject for
sacroiliac joint, and G0260, inject for sacroiliac joint anesthesia,
replace CPT code 27096 for reporting these injections in 2003. On page
66847, for CPT/HCPCS 27096, remove the status indicator of N and insert
a status indicator of E.
On page 66916, for CPT/HCPCS code 78459, description Heart muscle
imaging (PET), we assigned the wrong status indicator and did not
include needed payment information. On page 66916, remove the status
indicator of E and insert a status indicator of S, APC of 285, relative
weight of 18.1294, payment rate of $945.47, national unadjusted
copayment of $409.56, and minimum unadjusted copayment of $189.09.
On page 66958, for HCPCS codes A9522 (Indium111ibritumomabtiuxetan)
and A9523 (Y-90ibritumomabtiuxetan), we wrongly assigned status
indicator E, although the service is paid under the OPPS as a packaged
service for which payment is made as a part of a separately billable
service. On page 66958, remove the status indicator E and insert status
indicator N for both codes. These corrections are also shown in Tables
1 and 2 of this correction notice.
On page 66972, for CPT/HCPCS code E0481, Intrpulmnry percuss vent
sys, we wrongly assigned status indicator A, although the service is
not covered under Medicare. On page 66972, remove status indicator A
and insert status indicator E.
For the following codes on the pages identified, beginning on page
66974 and continuing as noted below on pages 67004, 67005, and 67006,
we wrongly assigned status indicator E (not paid under OPPS or not
covered) or A (paid under a payment system other than OPPS). These
codes are for services that are covered and paid under OPPS but for
which payment is packaged into payment for other OPPS services.
Therefore, they require the status indicator of ``N.'' We made this
correction on page 66974, for codes E0752, E0756, E0757, E0782, E0783,
E0785, E0786; on page 67004, for code L8606; on page 67005, for code
L8614; and on page 67006, for codes Q1001, Q1002, Q1003, Q1004, and
Q1005. These changes are also shown in Table 2--Corrections to Addendum
B of the November 1, 2002, Final Rule for corrections to Addendum B for
the codes identified above.
On page 66979, under CPT/HCPCS codes G0237, G0238, and G0239, we
inadvertently assigned these codes to the incorrect APC and assigned an
incorrect status indicator. Remove APC 0970 (group title New Technology
Level I ($0-$50)) and status indicator T and insert APC 0706 (group
title New Technology Level I) and status indicator of S. These
corrections are also shown in Table 2 of this correction notice.
On pages 66979 and 66980, for CPT/HCPCS codes G0281, G0282, and
G0283, we assigned the wrong status indicator. Remove the status
indicator A. Insert the status indicator E. These codes are not
effective for January 1, 2003; they are effective April 1, 2003.
On page 66979, for CPT/HCPCS code G0252, PET imaging initial dx, we
incorrectly assigned a status indicator, APC, payment rate, and minimum
unadjusted copayment. G0252 represents a noncovered condition under
Medicare coverage policy and no payment should be made for this
service. Remove status indicator S, APC, payment rate, and minimum
unadjusted copayment and insert status indicator E.
On page 66983, for CPT/HCPCS code J1327, remove status indicator of
N and insert status indicator of K, APC of 1607, relative weight of
0.1453, payment rate of $7.58, minimum unadjusted copayment of $1.52.
This change results from the change relating to Eptifibatide Injection
discussed above.
On page 66984, for CPT/HCPCS code J2260, Inj, milrinone lactate /
5ml, we incorrectly stated the description. Remove ``ml'' and insert
``mg''.
On page 67006, for CPT/HCPCS code Q0184, Metabolically active
tissue, we failed to include a condition code to indicate that the
grace period applies, although the code is removed for 2003. Insert
condition code DG.
III. Waiver of Proposed Rulemaking and Waiver of 30-Day Delay in
Effective Date
We ordinarily publish a notice of proposed rulemaking in the
Federal Register to provide a period for public comment before the
provisions of a notice take effect. We can waive this procedure,
however, if we find good cause that notice and comment procedure is
impracticable, unnecessary, or contrary to the public interest and
incorporate a statement of the finding and the reasons for it into the
notice issued.
In addition, we ordinarily provide a 30-day delay in the effective
date of the provisions of a notice. Section 553(d) of the
Administrative Procedure Act (5 U.S.C. section 553(d)) ordinarily
requires a 30-day delay in the effective date of final rules after the
date of their publication in the Federal Register. This 30-day delay in
effective date can be waived, however, if an agency finds for good
cause that the delay is impracticable, unnecessary, or contrary to the
public interest, and the agency incorporates a statement of the finding
and its reasons in the rule issued.
In this case, we believe that it is in the public interest to make
the corrections we identify above effective on January 1, 2003, without
the 30-day delay in effective date because to fail to do so would
result, in most cases, in underpayment of hospitals beginning January
1, 2003, with the implementation of the updated OPPS
[[Page 6640]]
rates. If we did not make these changes, hospitals would be paid
improperly, access to care may be impeded for beneficiaries, and the
preamble would not correctly explain the reasons for changes to policy
that were made in response to comments. In most cases, these errors
were the result of errors in mathematical calculations, inadvertent
publication of language we did not intend to publish, failure to apply
policies that we stated in the final rule had been applied, typographic
errors, or misstatements of fact. These corrections do not cause
reductions in payment for any other services.
We also find it unnecessary to undertake notice and comment
rulemaking procedures because the corrections in this notice are
technical in nature, reflecting the proper application of the policies
in the November 1, 2002, final rule, and do not change any of the
policies therein. Therefore, we find good cause to waive notice and
comment procedures and to waive the 30-day delay in effective date.
(Catalog of Federal Domestic Assistance Program No. 93.773,
Medicare--Hospital Insurance; and Program No. 93.774, Medicare--
Supplementary Medical Insurance Program)
Dated: January 29, 2003.
Ann Agnew,
Executive Secretary to the Department.
Note: The following tables are published for the convenience of
the reader. These tables reflect corrections made in section II of
the SUPPLEMENTARY INFORMATION.
BILLING CODE 4120-01-P
[[Page 6641]]
[GRAPHIC] [TIFF OMITTED] TR10FE03.000
[[Page 6642]]
[GRAPHIC] [TIFF OMITTED] TR10FE03.001
[[Page 6643]]
[GRAPHIC] [TIFF OMITTED] TR10FE03.002
[[Page 6644]]
[FR Doc. 03-2789 Filed 2-7-03; 8:45 am]
BILLING CODE 4120-01-C
 |